Valuation Latigo Biotherapeutics, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-11-06 EST			5-day change	1st Jan Change
12.60 ^USD	-3.15%		-9.68%	-

11-05	Latigo Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
09-20	Latigo Biotherapeutics, Inc.(NasdaqGS:LTGO) added to S&P TMI Index	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2026	2027	2028
Market Cap ¹	835.4	-	-
Change	-	-	-
Enterprise Value (EV) ¹	481.3	623.1	627.1
Change	-	29.45%	0.65%
P/E	-4.19x	-5.44x	-4.17x
PBR	-	-	-
PEG	0x	0.2x	-0.1x
Capitalization / Revenue	-	-	39.9x
EV / Revenue	-	-	29.9x
EV / EBITDA	-3.31x	-4.03x	-1.87x
EV / EBIT	-3.31x	-3.68x	-2.46x
EV / FCF	-	-	-
FCF Yield	-	-	-
Dividend per Share ²	-	-	-
Rate of return	-	-	-
EPS ²	-3.01	-2.318	-3.022
Distribution rate	-	-	-
Net sales ¹	-	-	20.96
EBITDA ¹	-145.2	-154.7	-335.7
EBIT ¹	-145.4	-169.5	-255.1
Net income ¹	-142.6	-161.3	-235.9
Net Debt ¹	-354	-212.3	-208.3
Reference price ²	12.60	12.60	12.60
Nbr of stocks (in thousands)	66,299	-	-
Announcement Date	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
LATIGO BIOTHERAPEUTICS, INC.	-4.19x	-	-3.31x	-	835M
WUXI APPTEC CO., LTD.	17.43x	6.6x	12.65x	1.71%	65.94B
LONZA GROUP AG	38.45x	6.85x	20.42x	0.85%	56.53B
ARGENX SE	30.07x	8.27x	26.77x	0.06%	56.88B
BEONE MEDICINES AG	49.29x	6.27x	34.36x	-.--%	46.49B
IQVIA HOLDINGS INC.	35.48x	3.35x	14.48x	-.--%	44.8B
REVOLUTION MEDICINES, INC.	-22.45x	63.4x	-21.48x	-.--%	41.59B
CELLTRION, INC.	35.89x	8.84x	23.03x	0.37%	35.35B
GENMAB A/S	37.6x	8.06x	26.12x	-.--%	33.29B
WUXI BIOLOGICS (CAYMAN) INC.	28.81x	6.09x	15.79x	-.--%	24.92B
Average	24.64x	13.08x	14.88x	0.33%	40.66B
Weighted average by Cap.	27.58x	12.58x	17.06x	0.44%